B cells in the pathogenesis of primary Sjögren syndrome

Nature Reviews Rheumatology

Volumn 14, Issue 3, 2018, Pages 133-145

  Nocturne, Gaëtane ^a   Mariette, Xavier ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; CHEMOKINE RECEPTOR CCR5; CXCL13 CHEMOKINE; INTERLEUKIN 21; MICRORNA; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TNFSF13B PROTEIN, HUMAN;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE SUBPOPULATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMORBIDITY; DNA DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; ENTEROVIRUS; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS C VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMORAL IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INNATE IMMUNITY; LACRIMAL GLAND; LATENT VIRUS INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE STRUCTURE; LYMPHOMA; MARGINAL ZONE B CELL; MEMORY CELL; PATHOGENESIS; PLASMA CELL; PLASMABLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY B LYMPHOCYTE; RETROVIRIDAE; REVIEW; SALIVARY GLAND; SJOEGREN SYNDROME; TFH CELL; VIRUS REACTIVATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; PATHOLOGY;

B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LYMPHOCYTE ACTIVATION; SJOGREN'S SYNDROME;

EID: 85042334230     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2018.1     Document Type: Review

References (159)

1. Qin, B. et al. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis. Ann. Rheum. Dis. 74, 1983-1989 (2015)
2. Bowman, S. J., Ibrahim, G. H., Holmes, G., Hamburger, J. &Ainsworth, J. R. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, U.K. Scand. J. Rheumatol. 33, 39-43 (2004)
3. Gottenberg, J. E. et al. Serum levels of B2 microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 8, e59868 (2013)
4. Jonsson, R., Theander, E., Sjostrom, B., Brokstad, K. &Henriksson, G. Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA 310, 1854-1855 (2013)
5. Theander, E. et al. Prediction of Sjogren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol. 67, 2427-2436 (2015)
6. Risselada, A. P., Looije, M. F., Kruize, A. A., Bijlsma, J. W. J. &van Roon, J. A. G. The role of ectopic germinal centers in the immunopathology of primary Sjogren's syndrome: a systematic review. Semin. Arthritis Rheum. 42, 368-376 (2013)
7. Zintzaras, E., Voulgarelis, M. &Moutsopoulos, H. M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch. Intern. Med. 165, 2337-2344 (2005)
8. Nocturne, G. et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's Syndrome. Arthritis Rheumatol. 68, 977-985 (2016)
9. Nocturne, G. &Mariette, X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat. Rev. Rheumatol. 9, 544-556 (2013)
10. Lessard, C. J. et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat. Genet. 45, 1284-1292 (2013)
11. Li, Y. et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren's syndrome at 7q11.23. Nat. Genet. 45, 1361-1365 (2013)
12. Nocturne, G. et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 122, 4068-4076 (2013)
13. Nocturne, G. et al. Germline variation of TNFAIP3 in primary Sjogren's syndrome-associated lymphoma. Ann. Rheum. Dis. 75, 780-783 (2016)
14. Taylor, K. E. et al. Genome-wide association analysis reveals genetic heterogeneity of Sjogren's syndrome according to ancestry. Arthritis Rheumatol. 69, 1294-1305 (2017)
15. Altorok, N. et al. Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjogren's syndrome. Arthritis Rheumatol. 66, 731-739 (2014)
16. Miceli-Richard, C. et al. Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at risk loci in primary Sjogren's syndrome. Ann. Rheum. Dis. 75, 933-940 (2016)
17. Imgenberg-Kreuz, J. et al. Genome-wide DNA methylation analysis in multiple tissues in primary Sjogren's syndrome reveals regulatory effects at interferon-induced genes. Ann. Rheum. Dis. 75, 2029-2036 (2016)
18. Konsta, O. D. et al. Defective DNA methylation in salivary gland epithelial acini from patients with Sjogren's syndrome is associated with SSB gene expression, anti-SSB/La detection, and lymphocyte infiltration. J. Autoimmun. 68, 30-38 (2016)
19. Cole, M. B. et al. Epigenetic signatures of salivary gland inflammation in Sjogren's syndrome. Arthritis Rheumatol. 68, 2936-2944 (2016)
20. Thabet, Y. et al. Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells. J. Autoimmun. 41, 175-181 (2013)
21. Peng, L. et al. MicroRNA profiling in Chinese patients with primary Sjogren syndrome reveals elevated miRNA 181a in peripheral blood mononuclear cells. J. Rheumatol. 41, 2208-2213 (2014)
22. Shi, H., Zheng, L., Zhang, P. &Yu, C. miR 146a and miR 155 expression in PBMCs from patients with Sjogren's syndrome. J. Oral Pathol. Med. 43, 792-797 (2014)
23. Pauley, K. M. et al. Altered miR 146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur. J. Immunol. 41, 2029-2039 (2011)
24. Alevizos, I., Alexander, S., Turner, R. J. &Illei, G. G. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum. 63, 535-544 (2011)
25. Wang-Renault, S. F. et al. Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjogren's syndrome. Ann. Rheum. Dis. 77, 133-140 (2018)
26. Pender, M. P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24, 584-588 (2003)
27. Borza, C. M. &Hutt-Fletcher, L. M. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat. Med. 8, 594-599 (2002)
28. Harley, J. B. &Zoller, E. E. What caused all these troubles, anyway? Epstein-Barr virus in Sjogren's syndrome reevaluated. Arthritis Rheumatol. 66, 2328-2330 (2014)
29. Fleck, M., Kern, E. R., Zhou, T., Lang, B. &Mountz, J. D. Murine cytomegalovirus induces a Sjogren's syndrome-like disease in C57Bl/6 lpr/lpr mice. Arthritis Rheum. 41, 2175-2184 (1998)
30. Iwakiri, D. et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 206, 2091-2099 (2009)
31. Küppers, R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3, 801-812 (2003)
32. He, B., Raab-Traub, N., Casali, P. &Cerutti, A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cellindependent Ig heavy chain class switching. J. Immunol. 171, 5215-5224 (2003)
33. Inoue, H. et al. Possible involvement of EBV-mediated a fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome. J. Immunol. 166, 5801-5809 (2001)
34. Croia, C. et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjogren's syndrome. Arthritis Rheumatol. 66, 2545-2557 (2014)
35. Minamitani, T. et al. Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A. Proc. Natl Acad. Sci. USA 112, 11612-11617 (2015)
36. Brauner, S. et al. H1N1 vaccination in Sjogren's syndrome triggers polyclonal B cell activation and promotes autoantibody production. Ann. Rheum. Dis. 76, 1755-1763 (2017)
37. Volkman, H. E. &Stetson, D. B. The enemy within: endogenous retroelements and autoimmune disease. Nat. Immunol. 15, 415-422 (2014)
38. Zeng, M. et al. MAVS, cGAS, and endogenous retroviruses in T independent B cell responses. Science 346, 1486-1492 (2014)
39. Mavragani, C. P. et al. Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. Arthritis Rheumatol. 68, 2686-2696 (2016)
40. Crow, M. K. Long interspersed nuclear elements (LINE 1): potential triggers of systemic autoimmune disease. Autoimmunity 43, 7-16 (2010)
41. Hung, T. et al. The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 350, 455-459 (2015)
42. Bohnhorst, J. O., Bjorgan, M. B., Thoen, J. E., Natvig, J. B. &Thompson, K. M. Bm1 Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167, 3610-3618 (2001)
43. Arbonneau, F. et al. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum. 54, 115-126 (2006)
44. Corneth, O. B. J. et al. Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheumatol. 69, 1313-1324 (2017)
45. Hansen, A. et al. Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum. 50, 1897-1908 (2004)
46. Roberts, M. E. P. et al. Primary Sjogren's syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. Arthritis Rheumatol. 66, 2558-2569 (2014)
47. Szabo, K., Papp, G., Szánto, A., Tarr, T. &Zeher, M. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjogren's syndrome and systemic lupus erythematosus. Clin. Exp. Immunol. 183, 76-89 (2016)
48. Hamza, N., Bos, N. A. &Kallenberg, C. G. M. B Cell populations and sub-populations in Sjogren's syndrome. Presse Med. 41, e475-483 (2012)
49. Hansen, A. et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 46, 2160-2171 (2002)
50. Mingueneau, M. et al. Cytometry by time of flight immunophenotyping identifies a blood Sjogren's signature correlating with disease activity and glandular inflammation. J. Allergy Clin. Immunol. 137, 1809-1821.e12 (2016)
51. Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity 43, 132-145 (2015)
52. Mei, H. E. et al. Plasmablasts with a mucosal phenotype contribute to plasmacytosis in SLE. Arthritis Rheumatol. 69, 2018-2018 (2017)
53. Jasiek, M. et al. A multicentre study of 95 biopsyproven cases of renal disease in primary Sjogren's syndrome. Rheumatology (Oxford) 56, 362-370 (2017)
54. Tengner, P., Halse, A. K., Haga, H. J., Jonsson, R. &Wahren-Herlenius, M. Detection of anti Ro/SSA and anti La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren's syndrome. Arthritis Rheum. 41, 2238-2248 (1998)
55. Fletcher, C. A. et al. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 36, 2504-2514 (2006)
56. Nguyen, C. Q., Kim, H., Cornelius, J. G. &Peck, A. B. Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6. NOD Aec1Aec2 mice is dependent on complement component 3. J. Immunol. 179, 2318-2329 (2007)
57. Shen, L. et al. Development of autoimmunity in IL 14a transgenic mice. J. Immunol. 177, 5676-5686 (2006)
58. Shen, L. et al. Central role for marginal zone B cells in an animal model of Sjogren's syndrome. Clin. Immunol. 168, 30-36 (2016)
59. Daridon, C. et al. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 54, 2280-2288 (2006)
60. Nocturne, G. &Mariette, X. Sjogren syndromeassociated lymphomas: an update on pathogenesis and management. Br. J. Haematol. 168, 317-327 (2015)
61. Mauri, C. &Blair, P. A. Regulatory B cells in autoimmunity: developments and controversies. Nat. Rev. Rheumatol. 6, 636-643 (2010)
62. Blair, P. A. et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140 (2010)
63. Lemoine, S., Morva, A., Youinou, P. &Jamin, C. Human T cells induce their own regulation through activation of B cells. J. Autoimmun. 36, 228-238 (2011)
64. Candando, K. M., Lykken, J. M. &Tedder, T. F. B10 cell regulation of health and disease. Immunol. Rev. 259, 259-272 (2014)
65. Menon, M., Blair, P. A., Isenberg, D. A. &Mauri, C. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44, 683-697 (2016)
66. Wang, R. X. et al. Interleukin 35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20, 633-641 (2014)
67. Shen, P. et al. IL 35 producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370 (2014)
68. Fogel, O. et al. Role of the IL 12/IL 35 balance in patients with Sjogren syndrome. J. Allergy Clin. Immunol. https://doi.org/10.1016/j.jaci.2017.07.041 (2017)
69. Puga, I. et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 13, 170-180 (2011)
70. Magri, G. et al. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat. Immunol. 15, 354-364 (2014)
71. Davies, R. et al. Patients with primary Sjogren's syndrome have alterations in absolute quantities of specific peripheral leucocyte populations. Scand. J. Immunol. 86, 491-502 (2017)
72. Mackay, F. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697-1710 (1999)
73. Mariette, X. et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 62, 168-171 (2003)
74. Lavie, F. et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J. Pathol. 202, 496-502 (2004)
75. Daridon, C. et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum. 56, 1134-1144 (2007)
76. Lavie, F. et al. B Cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand. J. Immunol. 67, 185-192 (2008)
77. Lahiri, A. et al. Specific forms of BAFF favor BAFF receptor-mediated epithelial cell survival. J. Autoimmun. 51, 30-37 (2014)
78. Nardelli, B. et al. Synthesis and release of B lymphocyte stimulator from myeloid cells. Blood 97, 198-204 (2001)
79. Litinskiy, M. B. et al. DCs induce CD40 independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3, 822-829 (2002)
80. Sjostrand, M. et al. The expression of BAFF is controlled by IRF transcription factors. J. Immunol. 196, 91-96 (2016)
81. Brkic, Z. et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis. 72, 728-735 (2013)
82. Ittah, M. et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR-and type I IFN-dependent and-independent pathways. Eur. J. Immunol. 38, 1058-1064 (2008)
83. Ittah, M. et al. Induction of B cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type. J. Innate Immun. 3, 200-207 (2011)
84. Groom, J. et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109, 59-68 (2002)
85. Ding, J. et al. BAFF overexpression increases lymphocytic infiltration in Sjogren's target tissue, but only inefficiently promotes ectopic B cell differentiation. Clin. Immunol. 169, 69-79 (2016)
86. Bombardieri, M. et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J. Immunol. 189, 3767-3776 (2012)
87. Salomonsson, S. et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 48, 3187-3201 (2003)
88. Pottier, L. et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J. Immunol. 182, 3540-3547 (2009)
89. Bombardieri, M., Lewis, M. &Pitzalis, C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat. Rev. Rheumatol. 13, 141-154 (2017)
90. Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037-1047 (1996)
91. Luther, S. A., Lopez, T., Bai, W., Hanahan, D. &Cyster, J. G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12, 471-481 (2000)
92. Nocturne, G. et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjogren's syndrome. Arthritis Rheumatol. 67, 3226-3233 (2015)
93. Barone, F. et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J. Immunol. 180, 5130-5140 (2008)
94. Barone, F. et al. IL 22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl Acad. Sci. USA 112, 11024-11029 (2015)
95. Ciccia, F. et al. Potential involvement of IL 22 and IL 22 producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann. Rheum. Dis. 71, 295-301 (2012)
96. Cella, M., Otero, K. &Colonna, M. Expansion of human NK 22 cells with IL 7, IL 2, and IL 1ß reveals intrinsic functional plasticity. Proc. Natl Acad. Sci. USA 107, 10961-10966 (2010)
97. Ciccia, F. et al. Interleukin (IL)-22 receptor 1 is overexpressed in primary Sjogren's syndrome and Sjogren-associated non-Hodgkin lymphomas and is regulated by IL 18. Clin. Exp. Immunol. 181, 219-229 (2015)
98. Kang, K. Y. et al. Impact of interleukin 21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin 21 and its expression in the labial salivary glands. Arthritis Res. Ther. 13, R179 (2011)
99. Maehara, T. et al. Selective localization of T helper subsets in labial salivary glands from primary Sjogren's syndrome patients. Clin. Exp. Immunol. 169, 89-99 (2012)
100. Gong, Y. Z. et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren's syndrome. J. Autoimmun. 51, 57-66 (2014)
101. Blokland, S. L. M. et al. Elevated CCL25 and CCR9 expressing T helper cells in salivary glands of primary Sjogren's syndrome patients: potential new axis in lymphoid neogenesis. Arthritis Rheumatol. 69, 2038-2051 (2017)
102. Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110-114 (2017)
103. Verstappen, G. M. et al. Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjogren's syndrome. Arthritis Rheumatol. 69, 1850-1861 (2017)
104. Gommerman, J. L., Rojas, O. L. &Fritz, J. H. Re thinking the functions of IgA(+) plasma cells. Gut Microbes 5, 652-662 (2014)
105. Szyszko, E. A. et al. Salivary glands of primary Sjogren's syndrome patients express factors vital for plasma cell survival. Arthritis Res. Ther. 13, R2 (2011)
106. Shiboski, C. H. et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann. Rheum. Dis. 76, 9-16 (2017)
107. Clancy, R. M. et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and-SSB/La antibodies in the pathogenesis of congenital heart block. J. Clin. Invest. 116, 2413-2422 (2006)
108. Shen, L. et al. Novel autoantibodies in Sjogren's syndrome. Clin. Immunol. 145, 251-255 (2012)
109. Baer, A. N., Petri, M., Sohn, J., Rosen, A. &Casciola-Rosen, L. Association of antibodies to interferoninducible protein 16 with markers of more severe disease in primary Sjogren's syndrome. Arthritis Care Res. 68, 254-260 (2016)
110. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Tolllike receptors. Nature 416, 603-607 (2002)
111. Lindop, R. et al. Molecular signature of a public clonotypic autoantibody in primary Sjogren's syndrome: a 'forbidden' clone in systemic autoimmunity. Arthritis Rheum. 63, 3477-3486 (2011)
112. Thurgood, L. A. et al. An immunodominant La/SSB autoantibody proteome derives from public clonotypes. Clin. Exp. Immunol. 174, 237-244 (2013)
113. Theander, E. et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis. 65, 796-803 (2006)
114. Smedby, K. E. et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J. Natl Cancer Inst. 98, 51-60 (2006)
115. Weng, M. Y., Huang, Y. T., Liu, M. F. &Lu, T. H. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann. Rheum. Dis. 71, 524-527 (2012)
116. Johnsen, S. J. et al. Risk of non-Hodgkin's lymphoma in primary Sjogren's syndrome: a population-based study. Arthritis Care Res. 65, 816-821 (2013)
117. Martin, T. et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 43, 908-916 (2000)
118. Bende, R. J. et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201, 1229-1241 (2005)
119. Song, H., Tong, D., Cha, Z. &Bai, J. C X C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma. Mol. Biol. Rep. 39, 8629-8635 (2012)
120. Theander, E. et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann. Rheum. Dis. 70, 1363-1368 (2011)
121. Risselada, A. P. et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjogren's syndrome. Ann. Rheum. Dis. 73, 1537-1540 (2014)
122. Haacke, E. A. et al. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjogren's syndrome are not predictive for parotid MALT lymphoma development. Ann. Rheum. Dis. 76, 1781-1784 (2017)
123. Quartuccio, L. et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B cell clonal expansion in the salivary glands. Rheumatology 52, 276-281 (2013)
124. Steri, M. et al. Overexpression of the cytokine BAFF and autoimmunity risk. N. Engl. J. Med. 376, 1615-1626 (2017)
125. Gottenberg, J. E. et al. No evidence for an association between the-871 T/C promoter polymorphism in the B cell-activating factor gene and primary Sjogren's syndrome. Arthritis Res. Ther. 8, R30 (2006)
126. Nezos, A. et al. B Cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J. Autoimmun. 51, 89-98 (2014)
127. Novak, A. J. et al. Genetic variation in B cell-activating factor is associated with an increased risk of developing B cell non-Hodgkin lymphoma. Cancer Res. 69, 4217-4224 (2009)
128. Papageorgiou, A. et al. A BAFF receptor His159Tyr mutation in Sjogren's syndrome-related lymphoproliferation. Arthritis Rheumatol. 67, 2732-2741 (2015)
129. Tobon, G. J. et al. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum. 62, 3447-3456 (2010)
130. Sisto, M. et al. A failure of TNFAIP3 negative regulation maintains sustained NF kB activation in Sjogren's syndrome. Histochem. Cell Biol. 135, 615-625 (2011)
131. Johnsen, S. J. et al. Low protein A20 in minor salivary glands is associated with lymphoma in primary Sjogren's syndrome. Scand. J. Immunol. 83, 181-187 (2016)
132. Musone, S. L. et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun. 12, 176-182 (2011)
133. Dass, S. et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541-1544 (2008)
134. Meijer, J. M. et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960-968 (2010)
135. Devauchelle-Pensec, V. et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann. Intern. Med. 160, 233-242 (2014)
136. Bowman, S. J. et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome. Arthritis Rheumatol. 69, 1440-1450 (2017)
137. Bootsma, H., Kroese, F. G. M. &Vissink, A. Rituximab in the treatment of Sjogren's syndrome: Is it the right or wrong drug? Arthritis Rheumatol. 69, 1346-1349 (2017)
138. Gottenberg, J. E. et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. 72, 1026-1031 (2013)
139. Mariette, X. et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis. 74, 526-531 (2015)
140. Seror, R. et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann. Rheum. Dis. 66, 351-357 (2007)
141. Pollard, R. P. E. et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. Ann. Rheum. Dis. 72, 146-148 (2013)
142. Lavie, F. et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66, 700-703 (2007)
143. Cornec, D. et al. Blood and salivary-gland BAFF-driven B cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome. J. Autoimmun. 67, 102-110 (2016)
144. Pers, J. O. et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum. 56, 1464-1477 (2007)
145. Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24 week randomized, placebo-controlled, phase IIb study. Arthritis Rheumatol. https://doi.org/10.1002/ art.40360 (2017)
146. Alexander, T. et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474-1478 (2015)
147. Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207-1219 (2015)
148. Mauri, C. &Menon, M. The expanding family of regulatory B cells. Int. Immunol. 27, 479-486 (2015)
149. Kalampokis, I., Yoshizaki, A. &Tedder, T. F. IL 10 producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 15 (Suppl. 1), S1 (2013)
150. Chtanova, T. et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173, 68-78 (2004)
151. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02291029 (2017)
152. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02334306 (2017)
153. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01782235 (2014)
154. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02149420 (2017)
155. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02610543 (2017)
156. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02631538 (2017)
157. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02067910 (2016)
158. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02915159 (2017)
159. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02780674 (2017)